Gamida Cell
Gamida Cell Q1 FY22: net loss $20.2M
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-22-025709
- Document
- 10-Q
Key figures from this report
These are the numbers Gamida Cell reported for Q1 FY22, the quarter ended Mar 31, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$20.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$42.1MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$25.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
